UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
     
 
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 1)*
     
 
KYMERA THERAPEUTICS, INC.
(Name of Issuer)
Common Stock, par value $0.0001 per share
(Title of Class of Securities)
501575104
(CUSIP Number)

Jonathan Biller
Vertex Pharmaceuticals Incorporated
50 Northern Avenue
Boston, Massachusetts 02210
(617) 341-6100
(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
June 1, 2023
(Date of Event Which Requires Filing of this Statement)
     
 
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.  

*
The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).



CUSIP No. 501575104
 


1.
 
Name of Reporting Person
 
Vertex Pharmaceuticals Incorporated
2.
 
Check the Appropriate Box if a Member of a Group
(a)          (b)  
 
3.
 
SEC Use Only
 
4.
 
Source of Funds
 
    WC
5.
 
Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)    
 
6.
 
Citizenship or Place of Organization
 
    Massachusetts
Number of
Shares
Beneficially
Owned by
Each
Reporting
Person
With
  
7.
Sole Voting Power
 
    0
  
8.
Shared Voting Power
 
    0
  
9.
Sole Dispositive Power
 
    0
  
10.
Shared Dispositive Power
 
    0
11.
 
Aggregate Amount Beneficially Owned by Each Reporting Person
 
    0
12.
 
Check if the Aggregate Amount in Row (11) Excludes Certain Shares    
 
13.
 
Percent of Class Represented by Amount in Row (11)
 
    0.0%
14.
 
Type of Reporting Person
 
    CO



This Amendment No. 1 (“Amendment No. 1”) to Schedule 13D relates to the common stock, par value $0.0001 per share (“Shares”), of Kymera Therapeutics, Inc., a Delaware corporation (“Issuer” or “Kymera”), and amends and supplements the initial statement on Schedule 13D filed on September 3, 2020 (as amended, the “Schedule 13D”). Except as specifically provided herein, this Amendment No. 1 does not modify any of the information previously reported in the Schedule 13D. Capitalized terms used but not defined in this Amendment No. 1 shall have the same meanings ascribed to them in the Schedule 13D.

Item 2. Identity and Background

Item 2 of the Schedule 13D is hereby amended by incorporating herein by reference the information set forth on the updated Schedule A attached hereto.

Item 5. Interest in Securities of Issuer

Item 5 of the Schedule 13D is hereby amended and restated as follows:

(a) As of the date hereof, Vertex does not beneficially own any Shares. To the knowledge of Vertex, no director or executive officer of Vertex beneficially owns any Shares.

(b) Not applicable.

(c) On June 1, 2023, Vertex sold 3,533,899 Shares in a block trade to a third party financial institution at a price of $26.92 per share. Except for the transactions described in this Amendment No. 1, Vertex has not entered into any transactions in the Shares during the past sixty days.

(d) Not applicable.

(e) As of June 1, 2023, Vertex ceased to beneficially own more than five percent of the outstanding Shares.



SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 
VERTEX PHARMACEUTICALS INCORPORATED
   
 
By:  
/s/ Jonathan Biller
 
 
Name: Jonathan Biller
 
Title: EVP and Chief Legal Officer
     
 
Date: June 5, 2023
































[Signature Page to Schedule 13D/A]



SCHEDULE A


The name, business address and present principal occupation or employment of each of the directors and executive officers of Vertex are set forth below. The business address of each director and executive officer is c/o Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston, Massachusetts 02210. Each director and executive officer is a citizen of the United States, except for Dr. Bozic who is a citizen of Canada. Mr. Arbuckle is also a citizen of the United Kingdom and Dr. Sanna is also a citizen of Italy.

Name
 
Present Principal Occupation or Employment
Jeffrey M. Leiden
 
 
Director of Vertex
Executive Chairman of Vertex
 
Reshma Kewalramani
 
Director of Vertex
Chief Executive Officer and President of Vertex
 
Sangeeta N. Bhatia
 
 
Director of Vertex
John J. and Dorothy Wilson Professor of Engineering at the Massachusetts Institute of Technology
 
Lloyd Carney

 
Director of Vertex

Alan Garber
 
 
Director of Vertex
Provost of Harvard University
 
Terrence C. Kearney
 
 
Director of Vertex 
Diana McKenzie

 
Director of Vertex

Bruce I. Sachs
 
 
Director of Vertex
General Partner at Charles River Ventures
 
Suketu (Suky) Upadhyay
 

 
Director of Vertex
Executive Vice President and Chief Financial Officer of Zimmer Biomet
 
David Altshuler

 
EVP, Global Research and Chief Scientific Officer of Vertex

Stuart Arbuckle
 
 
EVP and Chief Operating Officer of Vertex
Jonathan Biller
 
EVP and Chief Legal Officer of Vertex
 
Carmen Bozic
 
EVP, Global Medicines Development and Medical Affairs and Chief Medical Officer of Vertex
 
Amit Sachdev
 
 
EVP and Chief Patient Officer of Vertex
 
Bastiano Sanna

 
EVP and Chief of Cell and Genetic Therapies of Vertex

Nia Tatsis
 
EVP and Chief Regulatory and Quality Officer of Vertex
 
Charles Wagner
 
 
EVP and Chief Financial Officer of Vertex